Cargando…

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes

We investigated the efficacy and safety of switching to insulin glulisine (GLU) from other rapid-acting insulin analogs (Ra) in children with type 1 diabetes treated with multiple daily injections of insulin or continuous subcutaneous insulin infusion. A total of 26 children with type 1 diabetes wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Urakami, Tatsuhiko, Kuwabara, Remi, Habu, Masako, Okuno, Misako, Suzuki, Junichi, Takahashi, Shori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296707/ https://www.ncbi.nlm.nih.gov/pubmed/25621137 http://dx.doi.org/10.1111/jdi.12253

Ejemplares similares

Basal insulin requirement of youth with type 1 diabetes differs according to age
por: Urakami, Tatsuhiko, et al.
Publicado: (2013)

Pharmacologic Treatment Strategies in Children with Type 2 Diabetes Mellitus
por: Urakami, Tatsuhiko, et al.
Publicado: (2013)

Time to peak postprandial glucose levels in childhood-onset diabetic patients analyzed with a continuous glucose monitoring system
por: Suzuki, Junichi, et al.
Publicado: (2013)

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
por: Seufert, Jochen, et al.
Publicado: (2021)

Frequency of dawn phenomenon and its associations with age, HbA1c and diabetes duration in Japanese type 1 diabetes mellitus (T1DM) using the continuous glucose monitoring system (CGMS)
por: Yoshida, Ayako, et al.
Publicado: (2013)

Insulin glulisine in the management of diabetes
por: Yamada, Satoru
Publicado: (2009)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

Immunologic Tolerance to the Insulin Analogue Glulisine
por: Ozaki, Nobuaki, et al.
Publicado: (2010)

Association between Sex, Age, Insulin Regimens and Glycemic Control in Children and Adolescents with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2010)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

Efficacy and safety of alogliptin in a pediatric patient with maturity-onset diabetes of the young type 1
por: Tonouchi, Ryosuke, et al.
Publicado: (2017)

Insulin Glulisine May Cause a Disease Resembling Insulin Autoimmune Syndrome: Case Report
por: Kawasaki, Maki, et al.
Publicado: (2013)

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus
por: Lih, Anna, et al.
Publicado: (2010)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine
por: Ulrich, Heather, et al.
Publicado: (2007)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Gillis, Richard B., et al.
Publicado: (2021)

Frequent scanning using flash glucose monitoring contributes to better glycemic control in children and adolescents with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2021)

Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine
por: Miao, Raymond, et al.
Publicado: (2013)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Comparison of the clinical effects of intermittently scanned and real‐time continuous glucose monitoring in children and adolescents with type 1 diabetes: A retrospective cohort study
por: Urakami, Tatsuhiko, et al.
Publicado: (2022)

Effectiveness and Safety of Insulin Glulisine When Initiating Supplementary Prandial Insulin Treatment (SIT) in Insulin-Naïve Patients with Type 2 Diabetes: The Observational IGLU-SIT Study
por: Pfohl, Martin, et al.
Publicado: (2021)

Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes
por: Bolli, G B, et al.
Publicado: (2011)

Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
por: Morrow, Linda, et al.
Publicado: (2013)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

Insulin Resistance during Puberty in Non-obese Japanese Children
por: Morimoto, Shigeo, et al.
Publicado: (2011)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review
por: Fordan, Steve, et al.
Publicado: (2009)

Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine
por: Bergenstal, Richard M., et al.
Publicado: (2008)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

Insulin glargine in pediatric patients with type 1 diabetes in Japan
por: Urakami, Tatsuhiko, et al.
Publicado: (2014)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
por: Hidvégi, Tibor, et al.
Publicado: (2020)

MON-640 Endogenous Insulin and C-Peptide Suppression Test Using a Rapid-Acting Insulin Analog in the Diagnosis of Insulinoma
por: Laotaveerungrueng, Nattapong, et al.
Publicado: (2020)

A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
por: Baldwin, David, et al.
Publicado: (2012)

Case of type 2 diabetes possibly caused by excessive accumulation of visceral fat in a child born small‐for‐gestational age
por: Kuwabara, Remi, et al.
Publicado: (2020)

Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 Diabetes
por: Wu, Ted, et al.
Publicado: (2015)

Insulin Analogs and Cancer
por: Sciacca, Laura, et al.
Publicado: (2012)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
por: Young, Jason R., et al.
Publicado: (2010)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dbtbsi2ukbi06q2cn7snnpu660